SUMMARY

People without a functioning spleen include those with asplenia (absent splenic function with or without an anatomical spleen) and those with hyposplenia (reduced splenic function). Both asplenia and hyposplenia are associated with a lifelong risk of severe infection, mainly from encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type B). Care focuses on preventing infection through patient education, vaccination and antibiotics.

Core vaccines include pneumococcal, meningococcal, H. influenzae type B and influenza. Other routine adult vaccinations (e.g. diphtheria, tetanus and pertussis) are also recommended. Vaccination reduces but does not eliminate infection risk; therefore, prophylactic and emergency antibiotics are critical.

Daily antibiotic prophylaxis for at least 3 years after splenectomy is recommended because this is the period of highest risk. For patients with additional immunocompromise, lifelong daily antibiotic prophylaxis is recommended. All patients should have emergency antibiotics available to self-administer if symptoms of infection develop and immediate medical review is unavailable.

Patients should be educated about ongoing infection risk, the importance of maintaining up-to-date vaccinations, the role of prophylactic and emergency antibiotics, and when to seek urgent medical care.

Support and resources for patients and healthcare professionals are available through Spleen Australia.

 

Introduction

People without a functioning spleen, including those with asplenia (absent splenic function) and hyposplenia (reduced splenic function), are at increased risk of serious infections, which can progress rapidly to life-threatening sepsis. This syndrome, known as overwhelming post-splenectomy infection (OPSI), was first described following splenectomy;1,2 however, people with hyposplenism for other reasons (e.g. certain medical conditions) are vulnerable to the same pathogens and require similar infection prevention strategies.

Although many of these infections are preventable, gaps in care remain common. Approximately half of those without a functioning spleen have incomplete vaccination schedules,3 around 30% are not on recommended antibiotic prophylaxis4,5 and many are never identified as being at risk.6 Guidelines from Spleen Australia, updated in 2026, provide recommendations for infection prevention in people without a functioning spleen.7 This article focuses on recommendations in adults; for specific recommendations in children, refer to the Spleen Australia website.

 

Causes of asplenia and hyposplenia

It is estimated that between 20,000 and 50,000 Australians are living without a functioning spleen.8-12 Asplenia is most commonly due to splenectomy. However, functional asplenia (absent splenic function with an anatomical spleen) and hyposplenia can also occur in association with medical conditions (Box 1).5

Box 1 Medical conditions that can be associated with functional asplenia or hyposplenia13,14

Haematological: sickle cell disease, bone marrow transplantation, acute leukaemias, non-Hodgkin lymphoma, systemic mastocytosis, Langerhans cell histiocytosis, advanced breast cancer

Hepatic: alcoholic liver disease, chronic active hepatitis, liver cirrhosis, portal hypertension, primary biliary cirrhosis

Autoimmune: systemic lupus erythematosus, antiphospholipid syndrome, vasculitis, rheumatoid arthritis, Hashimoto thyroiditis

Gastrointestinal: coeliac disease, Crohn disease, ulcerative colitis, Whipple disease, dermatitis herpetiformis

Infectious: acquired immunodeficiency syndrome

Circulatory: splenic or coeliac artery thrombosis, splenic vein thrombosis

Miscellaneous: amyloidosis, sarcoidosis, splenic irradiation


 

Mechanism of increased infection risk in people without a functioning spleen

People without a functioning spleen are at increased susceptibility to severe infection from encapsulated bacteria. The spleen plays a critical role in both adaptive and innate immunity, acting as a repository for multiple immunologically active cells, including B and T cells.5,15 In the absence of a functioning spleen, the body is unable to clear pathogens effectively, allowing a minor infection to progress rapidly to life-threatening sepsis.

Streptococcus pneumoniae is the most common causative pathogen; however, other organisms, including Neisseria meningitidis, Haemophilus influenzae and Capnocytophaga canimorsus (the last particularly in the setting of animal bites), can also cause serious infection.5,16

Removal of the spleen may also increase vulnerability to other bacterial infections, for example Bordetella holmesii,17 and to bloodborne parasitic infections, particularly malaria, owing to the central role of the spleen in clearing parasitised red blood cells.18

Although these individuals may not be inherently at increased risk of contracting influenza and other respiratory viruses, a concurrent viral infection may predispose them to secondary bacterial sepsis.5,6

 

Assessment of splenic function

Assessment of splenic function should be considered in people with medical conditions that can be associated with functional asplenia or hyposplenia (Box 1), as well as in those presenting with meningococcal or pneumococcal sepsis in whom an underlying immune disorder is suspected.

Initial investigations include a full blood count and blood film.7 If a person is unexpectedly found to have Howell–Jolly bodies (small remnants of DNA within red blood cells that are normally removed by a functioning spleen) on a routine blood film, consider the patient’s history, including conditions associated with asplenia or hyposplenia (Box 1), trauma and abdominal surgery. If available, additional tests of splenic function (pitted red blood cell count or IgM-producing B cell count) may be ordered, followed by imaging for the presence of an anatomical spleen (e.g. ultrasound; the gold standard is a spleen scan with radio-labelled red blood cells).13,19

 

Prevention of serious infection in people without a functioning spleen

The main focus of care for people without a functioning spleen is preventing serious infections, such as OPSI, through 3 complementary strategies: patient education, vaccination and antibiotics.

Patient education

There is evidence that patients with better knowledge of their condition may have a lower risk of serious infection.20 Education for people living without a functioning spleen centres on several key messages about preventing infection. The most important message is that the risk of infection is lifelong and that infection can result in serious morbidity or death. For people who have undergone splenectomy, the risk of infection is highest during the first 3 years after splenectomy.

Patients should know about:

  • presenting early to care when symptoms of infection arise
  • the role of antibiotics, both as long-term prophylaxis and as emergency treatment when immediate medical review is unavailable
  • the importance of maintaining up-to-date vaccinations
  • the specific risks associated with animal bites, which can be mitigated by early presentation to care and antibiotic treatment
  • the risks related to overseas travel, particularly to malaria-endemic areas and regions where babesiosis (a parasitic infection of red blood cells) is transmitted by ticks.

All people without a functioning spleen should carry some form of medical alert, such as a laminated wallet card, medical alert bracelet or medallion, that identifies their increased risk of infection if they are found unconscious.7,16 Patients should inform their healthcare professional of their splenic status when presenting to care.

Spleen Australia provides a model for structured patient support.7 Spleen Australia supports over 13,000 active registered patients across Victoria, Queensland, Western Australia and Tasmania, with registration associated with a 69% reduction in infection risk.21 Upon registration, patients receive an education kit, a vaccination record card, a medical alert card, regular newsletters containing updated information and reminders, as well as individual education provided by a nurse consultant over the telephone. The Spleen Australia telephone service provides tailored advice, ongoing support and guidance regarding vaccination and antibiotics for both patients and healthcare providers. Registration is currently available for residents of Victoria, Queensland, Western Australia and Tasmania, with plans for national coverage. Medical recommendations and resources for patients and healthcare professionals are freely accessible on the Spleen Australia website.

Vaccination

Vaccination is a cornerstone of infection prevention in people without a functioning spleen. An appropriately administered and maintained vaccination schedule substantially reduces, but does not eliminate, the risk of serious infection.6,22 In Australia, core vaccines for people without a functioning spleen are funded through the National Immunisation Program.23

Core vaccines

Spleen Australia and the Australian Immunisation Handbook recommend vaccination against 4 key organisms: S. pneumoniae (pneumococcus), N. meningitidis (meningococcus; serogroups ACWY and B), H. influenzae type B and influenza.7,23

From 1 July 2026, a new pneumococcal vaccine is available for people with asplenia or hyposplenia. The 21-valent pneumococcal conjugate vaccine (21vPCV) is now recommended for all newly diagnosed adults and as a catch-up dose for those previously vaccinated with the older 13-valent conjugate and 23-valent polysaccharide vaccines. The 21vPCV dose should be given at least 12 months after the previous pneumococcal vaccination.23

Meningococcal vaccination includes both a quadrivalent conjugate vaccine targeting serogroups A, C, W and Y (MenACWY) and a recombinant protein vaccine targeting serogroup B (MenB). Both require a 2-dose primary series given at least 8 weeks apart, followed by boosters every 5 years for MenACWY and a single booster for MenB. The inclusion of MenB represents an important addition to the schedule, addressing the serogroup responsible for a substantial proportion of meningococcal disease in Australia.7,24

A single dose of H. influenzae type B conjugate vaccine is recommended, with no boosters required.

Annual influenza vaccination is strongly recommended, preferably in April before the influenza season.

Timing of initial course of core vaccines relative to splenectomy

The timing of the initial course of core vaccines is important. For elective splenectomy, vaccines should ideally be administered at least 2 weeks before surgery to allow an adequate immune response while the spleen is still in situ.23,25 Following emergency splenectomy, vaccines should ideally be administered at least 2 weeks postoperatively to obtain the best immune response. However, they may be given before hospital discharge, once the person is medically stable, if deemed beneficial for the patient.23

Timing of initial course of core vaccines relative to immunosuppressive therapy, chemotherapy or radiotherapy

Vaccination should ideally occur at least 2 weeks before starting treatment or be deferred until 3 to 6 months after completing treatment, once adequate immune reconstitution has occurred.23,25 The physician initiating the immunosuppressive therapy, chemotherapy or radiotherapy should always be consulted regarding optimal vaccination timing.

Additional vaccines

In addition to the core vaccines, clinicians should ensure patients remain up to date with all routine adult vaccinations, including diphtheria, tetanus and pertussis (dTpa) boosters. Other vaccines, such as respiratory syncytial virus (RSV), zoster and COVID-19, may also be recommended according to the Australian Technical Advisory Group on Immunisation, depending on age, severity of immunocompromise and Aboriginal and Torres Strait Islander status.23

People without a functioning spleen can safely receive live vaccines, such as measles, mumps and rubella (MMR), unless otherwise contraindicated.7,25

Practical considerations for administering vaccines

Multiple vaccines can be safely co-administered at the same visit, provided they are injected into separate sites. Up to 2 vaccines may be given in each deltoid muscle, spaced at least 2.5 cm apart.7

For previously vaccinated patients who received older formulations, the Australian Immunisation Handbook and Spleen Australia provide catch-up schedules to ensure coverage with current vaccines.7,23

Given the complexity of the vaccination schedule and the need for periodic boosters, registration with Spleen Australia, where available, can facilitate tracking and reminders for patients and clinicians.5,21

Antibiotics

Vaccination reduces but does not eliminate the risk of serious infection; therefore, prophylactic and emergency antibiotics, as well as early presentation to medical care, remain critical.

Antibiotic prophylaxis following splenectomy

The Australian Therapeutic Guidelines and Spleen Australia recommend daily antibiotic prophylaxis for at least 3 years following splenectomy, because this is the period of highest infection risk.7,26 The current recommendation in adults is oral amoxicillin 250 mg once daily or phenoxymethylpenicillin (penicillin V) 250 mg twice daily. For patients with additional immunocompromise or a history of serious infection, lifelong antibiotic prophylaxis is recommended. The evidence base for antibiotic prophylaxis rests largely on registry studies and randomised trials undertaken in children with haemoglobinopathies.21,27

Emergency antibiotics

All patients without a functioning spleen should have an emergency supply of antibiotics available at home and when travelling. If signs of bacterial infection develop (e.g. fever, rigors, chills, vomiting, diarrhoea) and immediate medical review (within 2 hours) is not available, adult patients should take amoxicillin 2 g immediately (four 500 mg capsules) then continue taking 1 g 8-hourly until medical review can occur.7

Antibiotic selection when the patient reports a beta-lactam allergy

In patients who report a beta-lactam allergy, a detailed allergy history should be obtained and, where appropriate, a formal penicillin allergy assessment undertaken.28,29 A structured approach to de-labelling of penicillin allergy is safe and effective, with high rates of successful de-labelling.30

If a beta-lactam allergy is confirmed, adults with nonsevere (immediate or delayed) penicillin hypersensitivity should receive cefuroxime 250 mg daily for antibiotic prophylaxis, and adults with severe penicillin hypersensitivity should receive azithromycin 250 mg daily.7,26

For emergency antibiotic treatment, cefuroxime 500 mg immediately is recommended for adults with nonsevere (immediate or delayed) penicillin hypersensitivity, followed by 500 mg 12-hourly if medical review is delayed.7 For patients with severe penicillin hypersensitivity, specialist advice should be sought (e.g. from an infectious diseases specialist, allergist or immunologist), including from Spleen Australia if needed.

Considerations for people who are planning overseas travel

Patients planning overseas travel should be reviewed at a clinic that provides specialised travel advice, ideally at least 4 to 6 weeks before departure.7,8 All core and routine vaccines should be confirmed as up to date. For travel to malaria-endemic areas, appropriate prophylaxis is essential alongside personal protective measures against mosquito bites.31,32 Travellers should be counselled on the risk of babesiosis in tick-endemic regions (including parts of North America, Europe, Asia and Africa) and advised on measures to avoid tick bites.5,7

 

Coordination of care

Preventive care can break down at multiple points: patients may be lost to follow-up after splenectomy or diagnosis of hyposplenia, vaccination schedules may not be completed and antibiotic prescriptions may lapse. Few patients carry a medical alert or emergency action plan.5,21 General practitioners are uniquely positioned to close these gaps by coordinating vaccination and antibiotic prophylaxis, screening for functional asplenia or hyposplenia, providing education and registering patients with Spleen Australia.

Effective education and care planning is a critical and often overlooked component of care. Patients should have a plan outlining how to recognise potential infection and when to use their emergency antibiotic supply and to seek urgent medical review.8,16 An alert indicating that the patient has asplenia or hyposplenia should be documented in the medical record so that any clinician who encounters the patient can act without delay.5,24

 

Conclusion

People without a functioning spleen are at lifelong risk of serious infection, but this risk can be substantially reduced through a systematic approach combining patient education, vaccination and prophylactic and emergency antibiotics. Spleen Australia can support ongoing preventive care through individualised vaccination plans, reminder systems and access to updated recommendations.

 

Key practice points

  •    Educate patients with asplenia or hyposplenia about their lifelong risk of infection.
  •    Document a vaccination plan and ensure patients receive core vaccines (pneumococcal, meningococcal, Haemophilus influenzae type B and influenza) and remain up to date with other routinely recommended vaccines.
  •    Provide daily prophylactic antibiotics for 3 years after splenectomy (lifelong for those with additional immunocompromise).
  •    Provide emergency antibiotics with clear written instructions on how and when to take them. Advise patients to have emergency antibiotics readily available at home and when travelling.
  •    Provide a written care plan for suspected infection, including when and where to seek urgent medical care.
  •    For patients planning overseas travel, ensure they receive a dedicated travel medicine review, ideally at least 4 to 6 weeks before departure. Advise patients about travel-related risks (e.g. malaria, tick bites), recommended vaccines and prophylaxis, if needed.
  •    Advise patients to carry a medical alert (e.g. bracelet, wallet card) indicating their splenic status.
  •    Register patients with Spleen Australia (if available in their jurisdiction).

This article was finalised on 6 October 2026.

Conflicts of interest: Ian Woolley has received consultancy fees from ViiV Healthcare, Gilead and Bristol Myers Squibb, and support for educational activities from ViiV Healthcare, Gilead and Pfizer.

All authors are on the guideline development committee for Spleen Australia.

This article is peer reviewed.

 

Australian Prescriber welcomes Feedback.

 

References

  1. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. Journal of Clinical Pathology 2001;54:214.
  2. Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late postsplenectomy infection. Br J Surg 1991;78:716–21.
  3. Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect Dis 2010;10:219.
  4. Wang J, Jones P, Cheng AC, Leder K. Adherence to infection prevention measures in a statewide spleen registry. Med J Aust 2014;200:538–40.
  5. Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions. Infect Drug Resist 2019;12:2839–51.
  6. Lee GM. Preventing infections in children and adults with asplenia. Hematology Am Soc Hematol Educ Program 2020;2020:328–35.
  7. Spleen Australia. Guidelines for Adults with Asplenia/Hyposplenism Aged >18 Years. 2026. [cited 2026 Jul 28]
  8. Kanhutu K, Jones P, Cheng AC, Grannell L, Best E, Spelman D. Spleen Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. Intern Med J 2017;47:848–55.
  9. Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust 2012;196:582–6.
  10. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014;99:392–8.
  11. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sorensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010;8:1413–6.
  12. Yong M, Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, et al. Mortality risk in splenectomised patients: a Danish population-based cohort study. Eur J Intern Med 2010;21:12–6.
  13. Lenti MV, Luu S, Carsetti R, Osier F, Ogwang R, Nnodu OE, et al. Asplenia and spleen hypofunction. Nat Rev Dis Primers 2022;8:71.
  14. Kirkineska L, Perifanis V, Vasiliadis T. Functional hyposplenism. Hippokratia 2014;18:7–11. https://europepmc.org/article/MED/25125944
  15. Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol 2019;4.
  16. Jones P, Leder K, Woolley I, Spelman D, Cameron P, Cheng A. Postsplenectomy infection - strategies for prevention in general practice. Australian Family Physician 2012;39:383–6. https://www.racgp.org.au/afp/2010/june/postsplenectomy-infection-strategies-for-preventio
  17. Shepard CW, Daneshvar MI, Kaiser RM, Ashford DA, Lonsway D, Patel JB, et al. Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 2004;38:799–804.
  18. Chotivanich K, Udomsangpetch R, McGready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002;185:1538–41.
  19. Cameron PU, Jones P, Gorniak M, Dunster K, Paul E, Lewin S, et al. Splenectomy associated changes in IgM memory B cells in an adult spleen registry cohort. PLoS One 2011;6:e23164.
  20. El-Alfy MS, El-Sayed MH. Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention? Hematol J 2004;5:77–80.
  21. Arnott A, Jones P, Franklin LJ, Spelman D, Leder K, Cheng AC. A Registry for Patients With Asplenia/Hyposplenism Reduces the Risk of Infections With Encapsulated Organisms. Clin Infect Dis 2018;67:557–61.
  22. Bonanni P, Grazzini M, Niccolai G, Paolini D, Varone O, Bartoloni A, et al. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum Vaccin Immunother 2017;13:359–68.
  23. Australian Technical Advisory Group on Immunisation. People with asplenia and hyposplenia. In: Australian Immunisation Handbook. Canberra: Department of Health, Disability and Ageing; 2026. [cited 2026 Aug 1]
  24. Ladhani SN, Fernandes S, Garg M, Borrow R, de Lusignan S, Bolton-Maggs PHB, et al. Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline. Br J Haematol 2024;204:1672–86.
  25. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44–100.
  26. Antibiotic. In: Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited; 2025.
  27. Siddins M, Downie J, Wise K, O'Reilly M. Prophylaxis against postsplenectomy pneumococcal infection. Australian and New Zealand Journal of Surgery 1990;60:183–7.
  28. Devchand M, Trubiano JA. Penicillin allergy: a practical approach to assessment and prescribing. Aust Prescr 2019;42:192–9.
  29. Mitri EA, Reynolds GK, Copaescu AM, Cox F, Waldron JL, Peter JG, et al. State-of-the-Art Review: Antibiotic Allergy-A Multidisciplinary Approach to Delabeling. Clin Infect Dis 2025;81:e74–e92.
  30. Loprete J, Richardson R, Bramah V, Comben S, Li T, Beiglari L, et al. Delabeling, safety, and impact of beta-lactam allergy testing: A systematic review. J Allergy Clin Immunol Glob 2023;2:100160.
  31. Kho S, Andries B, Poespoprodjo JR, Commons RJ, Shanti PAI, Kenangalem E, et al. High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. Clin Infect Dis 2019;68:51–60.
  32. Kotton CN, Kroger AT, Freedman DO. Immunocompromised Travelers. In: CDC Yellow Book. Centers for Disease Control and Prevention (US); 2025.
 

CPD for GPs questions

  • Identify and summarise three key points relevant to your scope of practice.
  • Identify the key clinical learnings that may be incorporated into the clinical assessment, work-up and/or management plan for appropriate patients.
  • If relevant, would you change any of your management strategies for those patients identified by appropriate screening, examination and investigation.

Submit answers

 

undefined

Deputy Director, Monash Infectious Diseases, Monash Health, Melbourne

Infectious Diseases Physician, Spleen Australia, Alfred Care Group, Bayside Health, Melbourne

Adjunct Clinical Professor, Monash University, Melbourne

undefined

Registered Nurse, The Alfred Hospital, Melbourne

Manager, Spleen Australia, Alfred Care Group, Bayside Health, Melbourne

Nenad Macesic

Infectious Diseases Physician, The Alfred Hospital, Melbourne

Director, Spleen Australia, Alfred Care Group, Bayside Health, Melbourne

Senior Research Fellow, Department of Infectious Diseases, Monash University, Melbourne

Deputy Director, Centre to Impact Antimicrobial Resistance, Monash University, Melbourne